A recent study suggests that people who donate blood regularly may have genetic changes in their blood that could in fact reduce the risk of developing cancer. It is conducted by the researchers at the Francis Crick Institute, and the study has now provided new insights into how and why blood cancers develop. The study is published in the journal Blood and was conducted by the scientists from Heidelberg and the German Red Cross blood donation center. There is yet a need for further research to confirm these findings.

What Did The Study Find?

The researchers examined the blood of two groups of healthy male donors in their 60s:

• One group had donated blood three times a year for 40 years.
• The other group had donated only about five times in total.

The goal was to analyze genetic mutations in their blood and assess whether frequent donation had any impact on their genetic makeup.

How Can Blood Donation Affect Stem Cells?

As and when people age, their blood and other cells naturally develop mutations and some of them can also increase the risk of cancer. When anyone donates blood, his or her body compensates by producing new blood cells, which can influence the genetic diversity of stem cells in the bone marrow. The study also found that both groups had a similar number of mutations. For instance the frequent donors had 217 mutations, while the irregular donors had 212 mutations.

However, the nature of these mutations differed. In the frequent donors, 50% of the mutations were of a type not associated with a high risk of blood cancers, compared to only 30% in the irregular donors.

Further laboratory analysis showed that these specific mutations behaved differently from those linked to leukemia, a type of blood cancer. When human blood stem cells with these mutations were injected into mice, they were found to be highly effective at producing red blood cells, which is considered a positive outcome.

Dr. Hector Huerga Encabo, one of the study authors, emphasized that these mutations do not indicate an increased risk of leukemia. The findings suggest that regular blood donation may influence how stem cells evolve, but whether this translates into a lower cancer risk remains uncertain.

Read More: Who Can Donate Blood To Whom?

Limitations

One notable disadvantage is the "healthy-donor effect"—because blood donors are often healthier than the general population, their lower cancer risk could be unrelated to blood donation.

Dominique Bonnet, senior researcher and head of a stem-cell laboratory at the Francis Crick Institute, stressed the need for larger studies with female volunteers to confirm the findings.

Despite ongoing research into potential health benefits for donors, the primary goal of blood donation remains saving lives. NHS Blood and Transplant emphasized that while the study is interesting, further research is required to draw firm conclusions. The organization also noted that blood supplies are currently critically low and encouraged eligible individuals to donate.

Also Read: How Long After a Tattoo or Piercing Can I Donate Blood?

While the confirmation of the Andes strain of hantavirus behind the outbreak aboard the cruise ship MV Hondius in the South Atlantic has raised significant concerns of human-to-human transmission, experts from the International Hantavirus Society, as well as the World Health Organization (WHO), stated that the situation does not raise the risk of a pandemic.

So far, eight cases have been reported, including three deaths. The WHO has also confirmed that six cases have tested positive for the Andes virus, which can spread from person to person, through PCR testing.

The International Hantavirus Society, in a statement, warned that the virus differs significantly from most other hantaviruses because it can spread between people.

Founded in 2001, the Hantavirus Society is a global organization of scientists, clinicians, and researchers focused on studying hantaviruses, including their ecology, pathogenesis, and prevention.

“The virus on board the MV Hondius is the Andes strain of hantavirus. It is serious,” said the WHO chief Tedros Adhanom Ghebreyesus, in an open statement on the social media platform X.

However, the WHO and the members of the Hantavirus Society maintained that the current outbreak is not another COVID-19 outbreak.

So, first, let us understand all about the Andes Virus.

What Is Andes Virus

The Andes virus is a rare but highly dangerous pathogen of hantavirus, found primarily in Argentina and Chile. It is the only type of hantavirus known to man to spread among humans.

Unlike many hantaviruses seen in Europe, Asia, and North America, which are typically transmitted from infected rodents to humans, the Andes virus has repeatedly shown evidence of person-to-person spread.

As per experts, transmission usually occurs in situations involving prolonged or close contact. But how close is a question that has been recurring. The Hantavirus Society answers this.

“Over the past decades, multiple outbreak investigations, household clusters, nosocomial events, and genomic analyses have provided convincing evidence that ANDV can be transmitted between individuals under specific close-contact conditions. These may include household exposure, intimate contact, caregiving without suitable personal protective equipment, and prolonged exposure in poorly ventilated or crowded settings,” it said.

Pointing out decades of outbreak investigations, hospital clusters, and genetic studies, experts emphasized: “Human-to-human transmission of Andes virus should no longer be considered hypothetical”.

The scientists stressed that current evidence does not suggest the virus spreads easily through casual community interaction in the way diseases like measles, influenza, or COVID-19 do.

Also Read: Hantavirus Outbreak: How MV Hondius Passengers Will Be Screened And Evacuated

Andes Virus: High Fatality Rate A Concern

But the Andes virus is associated with hantavirus pulmonary syndrome (HPS) — a severe respiratory illness that can rapidly become fatal. Reported fatality rates range from 20% to 40%, depending on the outbreak setting, quality of medical care, and surveillance capacity.

Recent surveillance data highlight the seriousness of the disease:

• Argentina reported 86 confirmed hantavirus cases in 2025, including 28 deaths.
• Chile reported 35 confirmed cases, including 7 deaths.

Why Continuous Monitoring Is Important?

The first major indication of person-to-person transmission emerged during the 1996 El Bolsón/Esquel outbreak. More recently, the 2018–2019 Epuyén outbreak infected 34 people after a single index case attended crowded social gatherings while symptomatic.

Strict public health interventions — including isolation, quarantine, and active contact tracing — reduced transmission.

Read More: Hantavirus: Israel Confirms 1st Case as UK, Spain Probe Suspected Infections; Should You Be Worried?

The Hantavirus Society noted that a confined environment aboard the MV Hondius means that passengers and crew may still be within the virus’s incubation period.

The scientists thus warned, "A negative PCR test shortly after exposure does not necessarily rule out future infection.” They recommend “ongoing monitoring, repeat testing where necessary, and antibody testing for close contacts”.

Experts are also examining whether transmission could occur during early or minimally symptomatic stages, rather than only after obvious illness begins.

While thalassemia is known widely as a blood disorder, its impact can extend far beyond anemia and transfusions, said experts on World Thalassemia Day today.

World Thalassemia Day is observed every year on May 8 to raise awareness about the inherited blood disorder caused by faulty genes.

The disorder, which often requires blood transfusions every fortnight, affects approximately 1.3 million people living with severe forms of thalassemia worldwide. About 1.5 percent of the global population is carriers, and the disease claims nearly 11,000 lives annually.

Speaking to HealthandMe, health experts raised concerns about the growing mental health and neurological challenges faced by patients, especially children and young adults living with the condition.

Dr. Praveen Gupta, Chairman – Marengo Asia International Institute of Neuro & Spine (MAIINS), Gurugram, shared that repeated blood transfusions are important and save the lives of thalassemia patients, but long-term transfusion therapy can potentially lead to neurological complications if not properly monitored.

“Chronic transfusions can cause iron overload, which is the accumulation of iron in critical organs such as the brain, and may impact cognitive and psychological function, as well as mood,” Dr. Gupta explained.

He added that "changes in oxygen supply and related complications may make patients more vulnerable to headaches, lethargy, or even undetected brain injury".

However, experts stress that most neurological complications can be prevented through multidisciplinary care, iron chelation therapy, and regular monitoring.

Can Thalassemia Affect Brain Development in Children?

The expert stated that thalassemia may also indirectly affect brain development in children, particularly when severe anemia continues for long periods and limits oxygen supply to the growing brain.

Dr. Gupta noted that poor oxygenation, nutritional deficiencies, iron overload from repeated transfusions, and metabolic complications may affect:

• Cognitive function
• Learning ability
• Attention span
• Overall neurodevelopment
• Early warning signs may include:
• Delayed speech
• Difficulty concentrating
• Poor school performance
• Frequent headaches
• Irritability
• Developmental delays

Also read: World Thalassemia Day 2026: Why Screening Before Marriage Or Pregnancy Is Important

Early Signs Parents Should Not Ignore

Dr. Vipin Khandelwal, Sr. Consultant Paediatric Haemato Oncology & BMT at Apollo Hospitals Navi Mumbai, told HealthandMe that thalassemia affects the blood’s ability to carry oxygen, and prolonged disruption can impact growth, immunity, bone health, and learning abilities.

“The early signs of thalassemia are often subtle, which is why many families miss them until anemia becomes severe,” he said.

Parents should watch for persistent symptoms such as:

• Unusual tiredness
• Pale appearance
• Poor appetite
• Difficulty gaining weight
• Delayed growth
• Delayed walking or speech
• Reduced stamina
• Bone pain
• Recurrent weakness

He stressed that while thalassemia is inherited, many serious complications can be prevented with early diagnosis, regular check-ups, timely transfusions, and proper iron monitoring.

Why Depression and Anxiety Are Common Among Thalassemics?

Read More: Hantavirus Updates Of The Day: 8 May 2026 - US CDC Classifies Outbreak As 'Level 3' Emergency

Further, the experts also highlighted risk of anxiety, stress, low self-esteem, and depression among people with thalassemia who face lifelong blood transfusions, frequent hospital visits, leading to physical fatigue, and fear of complications. Over time, these challenges may increase, many often go unnoticed or untreated.

Dr. Roshan Dikshit, Senior Consultant, Haematology & Bone Marrow Transplant at Aakash Healthcare, told HealthandMe that thalassemia is not only a physical health condition, but also an emotional and psychological challenge. He stressed the need to provide mental support to thalassemic patients.

“Frequent hospital visits, lifelong blood transfusions, fear of complications, and social limitations can increase the risk of anxiety, stress, and depression, especially among teenagers and young adults,” said Dr. Roshan Dikshit, Senior Consultant, Haematology & Bone Marrow Transplant at Aakash Healthcare.

According to Dr. Dikshit, many patients struggle with:

• Low self-esteem
• Isolation
• Emotional fatigue.

Importantly, these emotional challenges often go unnoticed.

“Mental health support should be considered an essential part of thalassemia care. Counseling, family support, social acceptance, and open communication can significantly improve a patient’s emotional well-being and quality of life,” he said.

He also emphasized that early psychological intervention can help patients cope better with the disease and reduce the long-term mental health burden associated with chronic illness.

Treatment of cancer during pregnancy and while the lady is nursing is one of the most complex challenges in oncology. It requires finely balancing the urgency of cancer treatment in the mother with the safety of the foetus. With advances in cancer research and treatment, it is now possible for oncologists to tailor treatment in a way that protects both the mother and the child without compromising cancer-related outcomes.

In an interview with Health and Men, Dr Jyoti Wadhwa, Principal Lead of Medical and Precision Oncology, Apollo Athenaa Women’s Cancer Centre, Delhi, spoke about the safe treatment of cancer during pregnancy.

Best time for cancer treatment during motherhood

The most important factor guiding anti-cancer treatment during pregnancy is the timing of the pregnancy. In the first trimester, the foetus is highly vulnerable since organ development is ongoing. Exposure to chemotherapy during this period carries a significant risk of miscarriage and congenital malformations, and hence such drugs are generally avoided. However, depending on the cancer type and its stage, doctors may consider surgery and, in some cases, even termination of pregnancy may be advised.

During the second and third trimesters, however, certain chemotherapy drugs can be safely administered, such as doxorubicin and cyclophosphamide, drugs that are commonly used for the treatment of breast cancer. When initiated, chemotherapy is usually stopped about three weeks before the expected date of delivery. It should be remembered that not all chemotherapy drugs are safe during pregnancy. Targeted therapies, hormonal therapies, and immunotherapies are usually avoided due to limited safety data and the possibility of potential harm to the foetus.

Is surgery safe during pregnancy?

Surgery can generally be performed safely during pregnancy, especially in the second trimester, when the risk of miscarriage and preterm labour is the lowest. Radiotherapy is generally deferred unless the treatment areas fall far from the uterus and adequate shielding can be ensured. If the woman is breastfeeding, it should be remembered that most anti-cancer drugs can pass into breast milk and harm the infant. Hence, breastfeeding must be stopped during this phase.

For the best outcomes, a multidisciplinary team approach is recommended for decision-making. This team should include not only oncologists but also obstetricians, paediatricians, and supportive care teams. The ultimate goal is to treat the mother effectively for cancer while minimising the risk to the foetus and the newborn child. It is very much doable in modern cancer care.

Precision oncology in pregnancy is more about planning ahead rather than immediate treatment execution. Many targeted therapies, such as bevacizumab and immunotherapies, are not safe during pregnancy and are hence deferred until after childbirth.